FF MDI (PT005) 9.6 μg

DRUG2 trials

Sponsors

Pearl Therapeutics, Inc.

Conditions

COPD, Chronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disorder

Phase 3

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

CompletedNCT02727660

Pearl Therapeutics, Inc.Chronic Obstructive Pulmonary Disorder

Start: 2016-04-29End: 2018-04-04Updated: 2019-09-26

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

CompletedNCT02937584

Pearl Therapeutics, Inc.COPD, Chronic Obstructive Pulmonary Disease

Start: 2016-12-29End: 2018-05-28Updated: 2019-07-24

Related Papers

Predictive modeling of COPD exacerbation rates using baseline risk factors

Therapeutic Advances in Respiratory Disease2022-01-0124 citations

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD

ERJ Open Research2020-04-018 citations

Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD

Therapeutic Advances in Respiratory Disease2020-01-018 citations

Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies

2019-09-28

Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD.

2018-05-082 citations